Senior onderzoeker Infectieziekten in de Eerste Lijn, surveillance
Publicatie
Publicatie datum
COVID-19 vaccine effectiveness against bedically attended symptomatic SARS-CoV-2 infection among target groups in europe, October 2024-January 2025, VEBIS Primary Care Network.
Laniece Delaunay, C., Verdasca, N., Monge, S., Domegan, L., Sève, N., Buda, S., Meijer, A., Lucaccioni, H., López Torrijos, M., McKenna, A., Enouf, V., Dürrwald, R., Velt, E. in 't, Valcárcel, Laiglesia, M.A., Bennett, C., Masse, S., Erdwiens, A., Hooiveld, M., Mlinarić, I., Túri, G., Rodrigues, A.P., Martínez-Baz, I., Lazar, M., Latorre-Margalef, N., Borges, V., Kaczmarek, M., Bacci, S., Kissling, E. COVID-19 vaccine effectiveness against bedically attended symptomatic SARS-CoV-2 infection among target groups in europe, October 2024-January 2025, VEBIS Primary Care Network. Influenza and Other Respiratory Viruses: 2025, 19(11), Art. nr. e70120
We estimated the effectiveness of 2024/25 COVID-19 vaccination against medically attended SARS-CoV-2 infection in Europe, among target groups. We included 3204 patients (8/139 cases vaccinated: 6%; 517/3065 controls vaccinated: 17%) from a multicentre, test-negative design study at primary care level. Vaccine effectiveness was 66% (95% CI: 34-85) overall, 73% (95% CI: 21-94) and 54% (95% CI: -3 to 83) in the first and second months post-vaccination, respectively. Overall vaccine effectiveness was 67% (95% CI: 33-86) among older adults (≥ 60 or ≥ 65 years). This relatively high COVID-19 VE (compared with previous seasons), as well as trends by time since vaccination, should be confirmed with additional data, as sample size was low.
We estimated the effectiveness of 2024/25 COVID-19 vaccination against medically attended SARS-CoV-2 infection in Europe, among target groups. We included 3204 patients (8/139 cases vaccinated: 6%; 517/3065 controls vaccinated: 17%) from a multicentre, test-negative design study at primary care level. Vaccine effectiveness was 66% (95% CI: 34-85) overall, 73% (95% CI: 21-94) and 54% (95% CI: -3 to 83) in the first and second months post-vaccination, respectively. Overall vaccine effectiveness was 67% (95% CI: 33-86) among older adults (≥ 60 or ≥ 65 years). This relatively high COVID-19 VE (compared with previous seasons), as well as trends by time since vaccination, should be confirmed with additional data, as sample size was low.